1.Guidelines for the Laboratory Diagnosis of Monkeypox in Korea
Ki Ho HONG ; Gab Jung KIM ; Kyoung Ho ROH ; Hyukmin LEE ; Ok Kyu PARK ; Taek Soo KIM ; Jae-Seok KIM ; Jaehyeon LEE ; Moon-Woo SEONG ; So Yeon KIM ; Jae-Sun PARK ; Younhee PARK ; Hee Jae HUH ; Namhee RYOO ; Hyun Soo KIM ; Heungsup SUNG ; Cheon Kwon YOO ;
Annals of Laboratory Medicine 2023;43(2):137-144
While the coronavirus disease 2019 pandemic is ongoing, monkeypox has been rapidly spreading in non-endemic countries since May 2022. Accurate and rapid laboratory tests are essential for identifying and controlling monkeypox. Korean Society for Laboratory Medicine and the Korea Disease Prevention and Control Agency have proposed guidelines for diagnosing monkeypox in clinical laboratories in Korea. These guidelines cover the type of tests, selection of specimens, collection of specimens, diagnostic methods, interpretation of test results, and biosafety. Molecular tests are recommended as confirmatory tests. Skin lesion specimens are recommended for testing in the symptomatic stage, and the collection of both blood and oropharyngeal swabs is recommended in the presymptomatic or prodromal stage.
2.Safety and efficacy of nilotinib in adult patients with chronic myeloid leukemia: a post-marketing surveillance study in Korea
Seo-Yeon AHN ; Sang Kyun SON ; Gyu Hyung LEE ; Inho KIM ; June-Won CHEONG ; Won Sik LEE ; Byung Soo KIM ; Deog-Yeon JO ; Chul Won JUNG ; Chu Myoung SEONG ; Jae Hoon LEE ; Young Jin YUH ; Min Kyoung KIM ; Hun-Mo RYOO ; Moo-Rim PARK ; Su-Hee CHO ; Hoon-Gu KIM ; Dae Young ZANG ; Jinny PARK ; Hawk KIM ; Seryeon LEE ; Sung-Hyun KIM ; Myung Hee CHANG ; Ho Sup LEE ; Chul Won CHOI ; Jihyun KWON ; Sung-Nam LIM ; Suk-Joong OH ; Inkyung JOO ; Dong-Wook KIM
Blood Research 2022;57(2):144-151
Background:
Nilotinib is a tyrosine kinase inhibitor approved by the Ministry of Food and Drug Safety for frontline and 2nd line treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). This study aimed to confirm the safety and efficacy of nilotinib in routine clinical practice within South Korea.
Methods:
An open-label, multicenter, single-arm, 12-week observational post-marketing surveillance (PMS) study was conducted on 669 Korean adult patients with Ph + CML from December 24, 2010, to December 23, 2016. The patients received nilotinib treatment in routine clinical practice settings. Safety was evaluated by all types of adverse events (AEs) during the study period, and efficacy was evaluated by the complete hematological response (CHR) and cytogenetic response.
Results:
During the study period, AEs occurred in 61.3% (410 patients, 973 events), adverse drug reactions (ADRs) in 40.5% (271/669 patients, 559 events), serious AEs in 4.5% (30 patients, 37 events), and serious ADRs in 0.7% (5 patients, 8 events). Furthermore, unexpected AEs occurred at a rate of 6.9% (46 patients, 55 events) and unexpected ADRs at 1.2% (8 patients, 8 events). As for the efficacy results, CHR was achieved in 89.5% (442/494 patients), and minor cytogenetic response or major cytogenetic response was achieved in 85.8% (139/162 patients).
Conclusion
This PMS study shows consistent results in terms of safety and efficacy compared with previous studies. Nilotinib was well tolerated and efficacious in adult Korean patients with Ph + CML in routine clinical practice settings.
3.Erratum: COVID-19 Molecular Testing in Korea:Practical Essentials and Answers From Experts Based on Experiences of Emergency Use Authorization Assays
Heungsup SUNG ; Kyoung Ho ROH ; Ki Ho HONG ; Moon-Woo SEONG ; Namhee RYOO ; Hyun Soo KIM ; Jaehyeon LEE ; So Yeon KIM ; Sook Won RYU ; Mi-Na KIM ; Myung Guk HAN ; Sang Won LEE ; Hyukmin LEE ; Cheon Kwon YOO ;
Annals of Laboratory Medicine 2021;41(1):126-127
4.2020 Korean Guidelines for Cardiopulmonary Resuscitation. Part 3. Adult basic life support
Kyoung-Jun SONG ; Sun Young LEE ; Gyu Chong CHO ; Giwoon KIM ; Jung-Youn KIM ; Jaehoon OH ; Je Hyeok OH ; Seung RYU ; Seung Mok RYOO ; Eun-Ho LEE ; Sung Oh HWANG ; Ju Young HONG ; Sung Phil CHUNG
Clinical and Experimental Emergency Medicine 2021;8(S):S15-S25
5.2020 Korean Guidelines for Cardiopulmonary Resuscitation. Part 3. Adult basic life support
Kyoung-Jun SONG ; Sun Young LEE ; Gyu Chong CHO ; Giwoon KIM ; Jung-Youn KIM ; Jaehoon OH ; Je Hyeok OH ; Seung RYU ; Seung Mok RYOO ; Eun-Ho LEE ; Sung Oh HWANG ; Ju Young HONG ; Sung Phil CHUNG
Clinical and Experimental Emergency Medicine 2021;8(S):S15-S25
6.COVID-19 Molecular Testing in Korea: Practical Essentials and Answers From Experts Based on Experiences of Emergency Use Authorization Assays
Heungsup SUNG ; Kyoung Ho ROH ; Ki Ho HONG ; Moon-Woo SEONG ; Namhee RYOO ; Hyun Soo KIM ; Jaehyeon LEE ; So Yeon KIM ; Sookwon YOO ; Mi-Na KIM ; Myung Guk HAN ; Sang Won LEE ; Hyukmin LEE ; Cheon Kwon YOO ;
Annals of Laboratory Medicine 2020;40(6):439-447
7.Guidelines for Laboratory Diagnosis of Coronavirus Disease 2019 (COVID-19) in Korea
Ki Ho HONG ; Sang Won LEE ; Taek Soo KIM ; Hee Jae HUH ; Jaehyeon LEE ; So Yeon KIM ; Jae-Sun PARK ; Gab Jung KIM ; Heungsup SUNG ; Kyoung Ho ROH ; Jae-Seok KIM ; Hyun Soo KIM ; Seung-Tae LEE ; Moon-Woo SEONG ; Namhee RYOO ; Hyukmin LEE ; Kye Chul KWON ; Cheon Kwon YOO
Annals of Laboratory Medicine 2020;40(5):351-360
The outbreak of coronavirus disease 2019 (COVID-19), which began in December 2019, is still ongoing in Korea, with >9,000 confirmed cases as of March 25, 2020. COVID-19 is a severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection, and real-time reverse transcription-PCR is currently the most reliable diagnostic method for COVID-19 around the world. Korean Society for Laboratory Medicine and the Korea Centers for Disease Prevention and Control propose guidelines for diagnosing COVID-19 in clinical laboratories in Korea. These guidelines are based on other related domestic and international guidelines, as well as expert opinions and include the selection of test subjects, selection of specimens, diagnostic methods, interpretation of test results, and biosafety.
8.Serotype Distribution and Antimicrobial Resistance of Invasive and Noninvasive Streptococcus pneumoniae Isolates in Korea between 2014 and 2016
Dong Chul PARK ; Si Hyun KIM ; Dongeun YONG ; In Bum SUH ; Young Ree KIM ; Jongyoun YI ; Wonkeun SONG ; Sae Am SONG ; Hee Won MOON ; Hae Kyung LEE ; Kyoung Un PARK ; Sunjoo KIM ; Seok Hoon JEONG ; Jaehyeon LEE ; Joseph JEONG ; Yu Kyung KIM ; Miae LEE ; Jihyun CHO ; Jong Wan KIM ; Kyeong Seob SHIN ; Sang Hyun HWANG ; Jae Woo CHUNG ; Hye In WOO ; Chae Hoon LEE ; Namhee RYOO ; Chulhun L CHANG ; Hyun Soo KIM ; Jayoung KIM ; Jong Hee SHIN ; Soo Hyun KIM ; Mi Kyung LEE ; Seong Gyu LEE ; Sook Jin JANG ; Kyutaeg LEE ; HunSuk SUH ; Yong Hak SOHN ; Min Jung KWON ; Hee Joo LEE ; Ki Ho HONG ; Kwang Sook WOO ; Chul Min PARK ; Jeong Hwan SHIN
Annals of Laboratory Medicine 2019;39(6):537-544
BACKGROUND: Several factors contribute to differences in Streptococcus pneumoniae serotype distribution. We investigated the serotype distribution and antimicrobial resistance of S. pneumoniae isolated between 2014 and 2016 in Korea. METHODS: We collected a total of 1,855 S. pneumoniae isolates from 44 hospitals between May 2014 and May 2016, and analyzed the serotypes by sequential multiplex PCR. We investigated the distribution of each serotype by patient age, source of the clinical specimen, and antimicrobial resistance pattern. RESULTS: The most common serotypes were 11A (10.1%), followed by 19A (8.8%), 3 (8.5%), 34 (8.1%), 23A (7.3%), and 35B (6.2%). The major invasive serotypes were 3 (12.6%), 19A (7.8%), 34 (7.8%), 10A (6.8%), and 11A (6.8%). Serotypes 10A, 15B, 19A, and 12F were more common in patients ≤5 years old, while serotype 3 was more common in patients ≥65 years old compared with the other age groups. The coverage rates of pneumococcal conjugate vaccine (PCV)7, PCV10, PCV13, and pneumococcal polysaccharide vaccine 23 were 11.8%, 12.12%, 33.3%, and 53.6%, respectively. Of the 1,855 isolates, 857 (46.2%) were multi-drug resistant (MDR), with serotypes 11A and 19A predominant among the MDR strains. The resistance rates against penicillin, cefotaxime, and levofloxacin were 22.8%, 12.5%, and 9.4%, respectively. CONCLUSIONS: There were significant changes in the major S. pneumoniae serotypes in the community. Non-PCV13 serotypes increased in patients ≤5 years old following the introduction of national immunization programs with the 10- and 13-polyvalent vaccines.
Cefotaxime
;
Humans
;
Immunization Programs
;
Korea
;
Levofloxacin
;
Multiplex Polymerase Chain Reaction
;
Penicillins
;
Pneumococcal Vaccines
;
Pneumonia
;
Serogroup
;
Streptococcus pneumoniae
;
Streptococcus
;
Vaccines
9.Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis.
Junshik HONG ; Seok Jin KIM ; Jae Sook AHN ; Moo Kon SONG ; Yu Ri KIM ; Ho Sup LEE ; Ho Young YHIM ; Dok Hyun YOON ; Min Kyoung KIM ; Sung Yong OH ; Yong PARK ; Yeung Chul MUN ; Young Rok DO ; Hun Mo RYOO ; Je Jung LEE ; Jae Hoon LEE ; Won Seog KIM ; Cheolwon SUH
Cancer Research and Treatment 2015;47(2):173-181
PURPOSE: This study was conducted to evaluate outcomes in adult patients with Burkitt lymphoma (BL) or Burkitt-like lymphoma treated with an rituximab plus hyper-CVAD (R-hyper-CVAD) regimen by focusing on tolerability and actual delivered relative dose intensity (RDI). MATERIALS AND METHODS: Patients > or = 20 years of age and pathologically diagnosed with BL or Burkitt-like lymphoma were treated with at least one cycle of R-hyper-CVAD as the first-line treatment in this study. Eligible patients' case report forms were requested from their physicians to obtain clinical and laboratory data for this retrospective study. RESULTS: Forty-three patients (median age, 51 years) from 14 medical centers in Korea were analyzed, none of which were infected with human immunodeficiency virus. The majority of patients had advanced diseases, and 24 patients achieved a complete response (75.0%). After a median follow-up period of 20.0 months, 2-year event-free and overall survival rates were 70.9% and 81.4%, respectively. Eleven patients (25.6%) were unable to complete the R-hyper-CVAD regimen, including six patients due to early death. The RDIs of adriamycin, vincristine, methotrexate, and cytarabine were between 60% and 65%, which means less than 25% of patients received greater than 80% of the planned dose of each drug. Poor performance status was related to the lower RDIs of doxorubicin and methotrexate. CONCLUSION: R-hyper-CVAD showed excellent treatment outcomes in patients who were suitable for dose-intense chemotherapy. However, management of patients who are intolerant to a dose-intense regimen remains problematic due to the frequent occurrence of treatmentrelated complications.
Adult
;
Burkitt Lymphoma
;
Cytarabine
;
Doxorubicin
;
Drug Therapy
;
Follow-Up Studies
;
HIV
;
Humans
;
Korea
;
Lymphoma*
;
Methotrexate
;
Retrospective Studies
;
Survival Rate
;
Vincristine
10.Characteristics and Risk Factors of Pediatric Eye Injury Patients in Emergency Department: Multicenter Cross-Sectional Study.
Suk Hee LEE ; Hyun Wook RYOO ; Jae Yun AHN ; Kang Suk SEO ; Jung Bae PARK ; Sang Do SHIN ; Kyoung Jun SONG ; Chang Bae PARK ; Kang Hyun LEE ; In Sool YOO ; Jin Seong CHO ; Hyun Ho RYU ; Tae Oh JEONG ; Seok Ran YEOM
Journal of the Korean Society of Emergency Medicine 2014;25(5):509-519
PURPOSE: This study was conducted in order to determine the characteristics and risk factors of pediatric eye injury patients in the emergency department and to offer strategies for prevention of pediatric eye injury. METHODS: This prospective study was conducted by use of a standardized eye injury survey of patients under the age of 16 years who were treated for ocular injury at nine emergency medical centers, from March to September of 2010. The following data were collected; general characteristics of the study population, type and location of injury, causative activities, and materials of injury. Risk factors associated with open-globe injury were analyzed by logistic regression. RESULTS: A total of 1,151 patients were enrolled in the study; 75% were male. The highest incidence was observed between the age of 11 and 16 years (34.5%); 79.2% of patients had closed globe injury. The most common type of injury was contusion (65.4%) in closed globe injury and penetration (5.1%) in open-globe injury. Eye injury occurred most commonly at home (48.6%), followed by school/institution (19.4%). The most common causative activity and material were play (42.4%) and person/animal/plant (17%). Application of eye protective equipment (odds ratio: 24.33; 95% CI: 11.32~52.29) was found to be a statistically significant factor for occurrence of an open-globe injury. CONCLUSION: Establishment of safety measures considering gender and age is important since characteristics of pediatric eye injury differ based on such risk factors. The risk of open-globe eye injury increased with application of personal protective equipment, therefore, public education and promotion to use protective equipment of adequate level would be considered important.
Contusions
;
Cross-Sectional Studies*
;
Education
;
Emergencies
;
Emergency Service, Hospital*
;
Eye Injuries*
;
Humans
;
Incidence
;
Logistic Models
;
Male
;
Pediatrics
;
Prospective Studies
;
Risk Factors*

Result Analysis
Print
Save
E-mail